JP2023535476A - Ｇｌｐ－１受容体アンタゴニスト - Google Patents

Ｇｌｐ－１受容体アンタゴニスト Download PDF

Info

Publication number
JP2023535476A
JP2023535476A JP2023505826A JP2023505826A JP2023535476A JP 2023535476 A JP2023535476 A JP 2023535476A JP 2023505826 A JP2023505826 A JP 2023505826A JP 2023505826 A JP2023505826 A JP 2023505826A JP 2023535476 A JP2023535476 A JP 2023535476A
Authority
JP
Japan
Prior art keywords
compound
syndrome
ser
lysr
hypoglycemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535476A5 (https=
Inventor
ブラウン，ジャイルズ・アルバート
コングリーヴ，マイルズ・スチュアート
スカリー，コナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of JP2023535476A publication Critical patent/JP2023535476A/ja
Publication of JP2023535476A5 publication Critical patent/JP2023535476A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023505826A 2020-07-27 2021-07-27 Ｇｌｐ－１受容体アンタゴニスト Pending JP2023535476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2011604.2 2020-07-27
GBGB2011604.2A GB202011604D0 (en) 2020-07-27 2020-07-27 GLP-1 receptor antagonists
PCT/GB2021/051921 WO2022023723A1 (en) 2020-07-27 2021-07-27 Glp-1 receptor antagonists

Publications (2)

Publication Number Publication Date
JP2023535476A true JP2023535476A (ja) 2023-08-17
JP2023535476A5 JP2023535476A5 (https=) 2024-07-31

Family

ID=72339360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505826A Pending JP2023535476A (ja) 2020-07-27 2021-07-27 Ｇｌｐ－１受容体アンタゴニスト

Country Status (8)

Country Link
US (1) US20230279053A1 (https=)
EP (1) EP4188409A1 (https=)
JP (1) JP2023535476A (https=)
CN (1) CN116171283A (https=)
AU (1) AU2021319051A1 (https=)
CA (1) CA3190422A1 (https=)
GB (1) GB202011604D0 (https=)
WO (1) WO2022023723A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020074927A2 (en) * 2018-10-12 2020-04-16 Heptares Therapeutics Limited Glp-1 receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020074927A2 (en) * 2018-10-12 2020-04-16 Heptares Therapeutics Limited Glp-1 receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 17, JPN5024001910, 2010, pages 6412 - 6420, ISSN: 0005802148 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 3, JPN5024001911, 2015, pages 1020 - 1037, ISSN: 0005802149 *
JOURNAL OF PEPTIDE SCIENCE, vol. 9, no. 8, JPN5024001909, 2003, pages 471 - 501, ISSN: 0005802147 *

Also Published As

Publication number Publication date
GB202011604D0 (en) 2020-09-09
US20230279053A1 (en) 2023-09-07
CA3190422A1 (en) 2022-02-03
CN116171283A (zh) 2023-05-26
EP4188409A1 (en) 2023-06-07
WO2022023723A1 (en) 2022-02-03
AU2021319051A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
AU2007319066B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
TWI770781B (zh) Gip/glp1共促效劑化合物
WO2022116693A1 (zh) 一类glp-1r受体激动剂化合物及其用途
US20250368709A1 (en) Glp-1 receptor antagonists
WO2024149080A1 (zh) 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
JP2023535476A (ja) Ｇｌｐ－１受容体アンタゴニスト
WO2017182873A2 (en) Peptide-oligourea foldamer compounds and methods of their use
JP7812338B2 (ja) Ｇｌｐ受容体アゴニスト
EP4121094A1 (en) Oral glp receptor agonists
CN115215787A (zh) 生长抑素受体5拮抗剂及其用途
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
ES2274268T3 (es) Compuestos y composiciones para el tratamiento de la diabetes y trastornos relacionados con la diabetes.
RU2838225C1 (ru) Агонисты рецепторов glp
WO2026073030A1 (en) Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260224